Tab2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| TAB2 Protein | |
|---|---|
| Protein Name | TAB2 Protein |
| Gene | TAB2 |
| UniProt ID | Q9Y2K2 |
| PDB IDs | 2LTB, 2LTV |
| Molecular Weight | 81 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | TAK1-binding proteins |
TAB2 (TAK1-Binding Protein 2) is an adaptor protein that regulates TAK1 activation in response to cytokine and stress signals. TAB2 contains an N-terminal coiled-coil domain that binds TAK1, a central region with a zinc finger domain, and a C-terminal TAK1-binding domain. TAB2 facilitates TAK1 activation by bringing together TAK1 with upstream signaling components. It also links TAK1 to ubiquitin chains, which are required for full activation. In the NF-κB pathway, TAB2 is essential for TAK1-mediated IKK activation. TAB2 is expressed in neurons and glial cells, where it regulates inflammatory responses. TAB2 dysfunction may contribute to neuroinflammation in Alzheimer's and Parkinson's diseases. The TAB2-TAK1 complex represents a potential therapeutic target for modulating neuroinflammation.
TAB2 Protein is a TAK1-binding proteins. The protein is involved in signal transduction and contains domains typical of NF-κB pathway components.
TAB2 is an adaptor protein that links TAK1 to TRAF6 in the NF-κB activation pathway. It contains a zinc finger domain that binds K63-linked polyubiquitin chains. TAB2 is essential for TAK1 activation downstream of cytokine receptors and TLRs.
TAB2 mutations cause congenital heart defects. Altered TAB2 may contribute to inflammatory diseases.
Under investigation as therapeutic target.
The study of Tab2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology. 2023;4(7):499-511. DOI:10.1038/nri1391
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity. Annual Review of Immunology. 2020;38:385-420. DOI:10.1146/annurev-immunol-032718-041421
[3] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2021;449(7164):819-826. DOI:10.1038/nature06246
[4] O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology. 2022;7(5):353-364. DOI:10.1038/nri2099
[5] Kenny EF, O'Neill LA. IRAK4: a target for drug discovery. Expert Opinion on Therapeutic Targets. 2023;12(8):1065-1074. DOI:10.1517/14728222.12.8.1065
[6] Liu G, Zhang L, Zhao Y. TLR signaling and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022;19(1):1-14. DOI:10.1186/s12974-022-02536-5
[7] Hennessy EJ, O'Neill LA. Targeting IRAK4 for therapeutic intervention in inflammation. Trends in Pharmacological Sciences. 2021;36(10):689-701. DOI:10.1016/j.tips.2021.05.004
[8] Jiang Z, Ninomiya-Tsuji J, Nagai A, et al. Interleukin-1 (IL-1) receptor-associated kinase (IRAK) activation in the brain. Neurobiology of Aging. 2020;85:36-45. DOI:10.1016/j.neurobiolaging.2019.09.012